Soligenix, Inc. (SNGX) |
|
0.5357 0.003 (0.51%)
|
09-27 16:00 |
|
Open: |
0.535801 |
Pre. Close: |
0.533 |
|
High:
|
0.54 |
Low:
|
0.53 |
|
Volume:
|
31,926 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:22:11 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.64 One year: 0.75 |
| Support: |
Support1: 0.48  Support2: 0.43 |
| Resistance: |
Resistance1: 0.55 Resistance2: 0.64 |
| Pivot: |
0.5 |
| Moving Average: |
MA(5): 0.52 MA(20): 0.49
MA(100): 0.63 MA(250): 3.92 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 83.7 %D(3): 79.4 |
| RSI: |
RSI(14): 56.2 |
| 52-week: |
High: 10.94 Low: 0.41 |
| Average Vol(K): |
3-Month: 136 (K) 10-Days: 90 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SNGX ] has closed below upper band by 21.3%. Bollinger Bands are 67.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.54 - 0.54 |
0.54 - 0.55 |
|
Low:
|
0.52 - 0.53 |
0.53 - 0.53 |
|
Close:
|
0.53 - 0.54 |
0.54 - 0.54 |
|
Company Description |
|
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. |
Headline News |
Mon, 25 Sep 2023
BridgeBio Pharmas Strategic Financial Moves to Advance Genetic ... - Best Stocks
Mon, 25 Sep 2023
Soligenix, Inc. (SNGX) Achieves Two-Year Stability with Bivalent ... - StreetInsider.com
Wed, 06 Sep 2023
Palisade Bio Partners with Giiant Pharma to Revolutionize IBD ... - Best Stocks
Thu, 24 Aug 2023
SNGX: HyBryte™ Expanded Treatment Trial Underway - Yahoo Finance
Mon, 21 Aug 2023
Soligenix Announces Recent Accomplishments And Second Quarter ... - PR Newswire
Fri, 11 Aug 2023
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
10 (M) |
|
% Held by Insiders
|
8.47e+006 (%) |
|
% Held by Institutions
|
0.1 (%) |
|
Shares Short
|
97 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.043e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
47 |
|
Return on Equity (ttm)
|
-37.2 |
|
Qtrly Rev. Growth
|
996320 |
|
Gross Profit (p.s.)
|
-5.69 |
|
Sales Per Share
|
-116.35 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-2.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.5 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
1.51 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
24880 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
